---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-274596"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:27:10.445015+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Intellia reports positive lonvo-z HAE data: 97% attack-free; nex-z shows 87% TTR reduction at 36 months

## Summary
- Lonvo-z pooled Phase 1/2: 97% (31/32) attack-free and LTP-free; 75% attack-free for ≥7 months (up to 32 months).
- Mean kallikrein reduction 89% at month 24; well-tolerated safety up to 3 years with no long-term risks.
- Nex-z Phase 1: 87% mean serum TTR reduction at 36 months (n=9); all-cause mortality rate 3.9 vs 12.7 per 100 patient-years (HR 0.27, p=0.009) vs matched cohort.
- Nex-z showed disease stability or improvement on multiple cardiomyopathy markers at 24 months; 81% stable/improved NYHA class.
- FDA clinical hold on nex-z Phase 3 MAGNITUDE/MAGNITUDE-2 trials; company working to address.

## SEC filing metadata
- accession: 0001193125-25-274596
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312525274596/0001193125-25-274596-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312525274596/d12611d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-274596
- JSON: https://secwatch.observer/filing/0001193125-25-274596.json
- Plain text: https://secwatch.observer/filing/0001193125-25-274596.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.